AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioVie Advances Parkinson’s, Long COVID, and Liver Disease Programs Ahead of 2026
ByAinvest
Wednesday, Dec 17, 2025 11:41 am ET1min read
BIVI--
BioVie is advancing its drug candidates Bezisterim and BIV201 for Parkinson's disease, long COVID, and liver disease. Bezisterim has shown promising results in prior studies, and BioVie is launching a new clinical trial for earlier-stage Parkinson's disease. The company is also conducting a larger trial for long COVID and has received FDA authorization to advance BIV201 directly into a Phase 3 clinical trial. BioVie expects 2026 to be a transformational year with multiple clinical data readouts and the potential initiation of a pivotal Phase 3 study.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet